Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 7/20 | 0.48 |
| ▸ | FDPS | P14324 | 11/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25873393 | 1.00 | GGPS1 (0.48) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL19961999 | 0.77 | GGPS1 (0.65) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL19840566 | 0.77 | GGPS1 (0.65) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL24067447 | 0.77 | GGPS1 (0.65) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL29164627 | 0.77 | LPAR3 (0.56) | GGPS1FDPSLPAR3LPAR2 | |
| Dodecane SCHEMBL28904661 | 0.77 | LPAR3 (0.56) | GGPS1FDPSLPAR3LPAR2 | |
| Tridecane SCHEMBL5319320 | 0.77 | LPAR3 (0.56) | GGPS1FDPSLPAR3LPAR2 | |
| SCHEMBL28533054 | 0.77 | LPAR3 (0.56) | GGPS1FDPSLPAR3LPAR2 | |
| SCHEMBL27574135 | 0.76 | GGPS1 (0.63) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL3980053 | 0.76 | GGPS1 (0.63) | GGPS1FDPSLPAR3SMPD1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | GGPS1 593/4885FDPS 2964/4885LPAR3 2478/4885 |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | GGPS1 593/4885FDPS 2964/4885LPAR3 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.